INCB186748

INCB186748 is an investigational small molecule inhibitor developed by Incyte for the treatment of advanced or metastatic solid tumors harboring the KRAS G12D mutation. It represents a new wave of targeted therapies designed to directly inhibit oncogenic KRAS G12D, a mutation commonly found in pancreatic, colorectal, and other solid tumors. The drug is currently being evaluated in Phase 1 clinical trials as both monotherapy and in combination with other agents (such as cetuximab) for patients who have progressed on or are intolerant to standard treatments[2][3][5][7]. Its precise mechanism of action is described as selective inhibition of KRAS G12D[7], aiming to block tumor growth driven by this specific genetic alteration.